SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives final approval from USFDA for Oxybutynin Chloride Extended-Release Tablets

28 Jun 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg, and 15 mg. The drug is used to treat symptoms of overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. The estimated sale for Oxybutynin Chloride Extended-Release Tablets is $150.9 million.

The group now has more than 120 approvals and has so far filed over 300 ANDAs, since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

942.55 0.00 (0.00%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×